The number of implants in Europe is progressively increasing and approximately in 45% of cases is required anti-thrombotic therapy. Novel oral anticoagulants (NOACs) showed to have a good safety profile, in particular regarding bleeding complications compared to vitamin-K antagonists (VKAs). Some trials investigated the role of the two managements (VKAs and NOAC) in EP procedures but comparison between the two approaches still has to be extrapolated from the trials. In particular a regimen of non-discontinuation for VKAs is superior to heparin bridging and the management of NOACs, discontinuation vs. prosecution, showed no benefit for a particular strategy. Purpose of the registry is to evaluate the burden of bleeding complications in EP procedures between a non-discontinuation management of VKA and NOACs.


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account